235 related articles for article (PubMed ID: 31838403)
1. Clinical validation of a prognostic 11-gene expression profiling score in prospectively collected FFPE tissue of patients with AJCC v8 stage II cutaneous melanoma.
Amaral TMS; Hoffmann MC; Sinnberg T; Niessner H; Sülberg H; Eigentler TK; Garbe C
Eur J Cancer; 2020 Jan; 125():38-45. PubMed ID: 31838403
[TBL] [Abstract][Full Text] [Related]
2. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma.
Keller J; Schwartz TL; Lizalek JM; Chang ES; Patel AD; Hurley MY; Hsueh EC
Cancer Med; 2019 May; 8(5):2205-2212. PubMed ID: 30950242
[TBL] [Abstract][Full Text] [Related]
3. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
Zager JS; Gastman BR; Leachman S; Gonzalez RC; Fleming MD; Ferris LK; Ho J; Miller AR; Cook RW; Covington KR; Meldi-Plasseraud K; Middlebrook B; Kaminester LH; Greisinger A; Estrada SI; Pariser DM; Cranmer LD; Messina JL; Vetto JT; Wayne JD; Delman KA; Lawson DH; Gerami P
BMC Cancer; 2018 Feb; 18(1):130. PubMed ID: 29402264
[TBL] [Abstract][Full Text] [Related]
4. Interim analysis of survival in a prospective, multi-center registry cohort of cutaneous melanoma tested with a prognostic 31-gene expression profile test.
Hsueh EC; DeBloom JR; Lee J; Sussman JJ; Covington KR; Middlebrook B; Johnson C; Cook RW; Slingluff CL; McMasters KM
J Hematol Oncol; 2017 Aug; 10(1):152. PubMed ID: 28851416
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients.
Gambichler T; Tsagoudis K; Kiecker F; Reinhold U; Stockfleth E; Hamscho R; Egberts F; Hauschild A; Amaral T; Garbe C
Eur J Cancer; 2021 Jan; 143():11-18. PubMed ID: 33278769
[TBL] [Abstract][Full Text] [Related]
6. Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients.
Lee JH; Saw RP; Thompson JF; Lo S; Spillane AJ; Shannon KF; Stretch JR; Howle J; Menzies AM; Carlino MS; Kefford RF; Long GV; Scolyer RA; Rizos H
Ann Oncol; 2019 May; 30(5):815-822. PubMed ID: 30860590
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma.
Hsueh EC; DeBloom JR; Lee JH; Sussman JJ; Covington KR; Caruso HG; Quick AP; Cook RW; Slingluff CL; McMasters KM
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036233
[TBL] [Abstract][Full Text] [Related]
8. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
[TBL] [Abstract][Full Text] [Related]
9. Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma.
Kanaki T; Stang A; Gutzmer R; Zimmer L; Chorti E; Sucker A; Ugurel S; Hadaschik E; Gräger NS; Satzger I; Schadendorf D; Livingstone E
Eur J Cancer; 2019 Sep; 119():18-29. PubMed ID: 31401470
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma.
Eggermont AMM; Blank CU; Mandala M; Long GV; Atkinson VG; Dalle S; Haydon A; Lichinitser M; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJ; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Lupinacci R; Krepler C; Ibrahim N; Kicinski M; Marreaud S; van Akkooi AC; Suciu S; Robert C
Eur J Cancer; 2019 Jul; 116():148-157. PubMed ID: 31200321
[TBL] [Abstract][Full Text] [Related]
11. A nine-gene signature predicting clinical outcome in cutaneous melanoma.
Brunner G; Reitz M; Heinecke A; Lippold A; Berking C; Suter L; Atzpodien J
J Cancer Res Clin Oncol; 2013 Feb; 139(2):249-58. PubMed ID: 23052696
[TBL] [Abstract][Full Text] [Related]
12. Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study.
Podlipnik S; Carrera C; Boada A; Richarz NA; López-Estebaranz JL; Pinedo-Moraleda F; Elosua-González M; Martín-González MM; Carrillo-Gijón R; Redondo P; Moreno E; Malvehy J; Puig S
J Eur Acad Dermatol Venereol; 2019 May; 33(5):857-862. PubMed ID: 30702163
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of primary cutaneous melanoma and clinical outcome.
Winnepenninckx V; Lazar V; Michiels S; Dessen P; Stas M; Alonso SR; Avril MF; Ortiz Romero PL; Robert T; Balacescu O; Eggermont AM; Lenoir G; Sarasin A; Tursz T; van den Oord JJ; Spatz A;
J Natl Cancer Inst; 2006 Apr; 98(7):472-82. PubMed ID: 16595783
[TBL] [Abstract][Full Text] [Related]
14. Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I-IIA cutaneous melanoma.
Meyer S; Buser L; Haferkamp S; Berneburg M; Maisch T; Klinkhammer-Schalke M; Pauer A; Vogt T; Garbe C
Eur J Cancer; 2023 Mar; 182():77-86. PubMed ID: 36753835
[TBL] [Abstract][Full Text] [Related]
15. Sex-Based Differences in Melanoma Survival in a Contemporary Patient Cohort.
Hieken TJ; Glasgow AE; Enninga EAL; Kottschade LA; Dronca RS; Markovic SN; Block MS; Habermann EB
J Womens Health (Larchmt); 2020 Sep; 29(9):1160-1167. PubMed ID: 32105561
[No Abstract] [Full Text] [Related]
16. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690.
Kashani-Sabet M; Nosrati M; Miller JR; Sagebiel RW; Leong SPL; Lesniak A; Tong S; Lee SJ; Kirkwood JM
Clin Cancer Res; 2017 Nov; 23(22):6888-6892. PubMed ID: 28790109
[No Abstract] [Full Text] [Related]
17. A single-institution validation of the AJCC staging system for stage IV melanoma.
Neuman HB; Patel A; Ishill N; Hanlon C; Brady MS; Halpern AC; Houghton A; Coit DG
Ann Surg Oncol; 2008 Jul; 15(7):2034-41. PubMed ID: 18465172
[TBL] [Abstract][Full Text] [Related]
18. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model.
Eggermont AMM; Bellomo D; Arias-Mejias SM; Quattrocchi E; Sominidi-Damodaran S; Bridges AG; Lehman JS; Hieken TJ; Jakub JW; Murphree DH; Pittelkow MR; Sluzevich JC; Cappel MA; Bagaria SP; Perniciaro C; Tjien-Fooh FJ; Rentroia-Pacheco B; Wever R; van Vliet MH; Dwarkasing J; Meves A
Eur J Cancer; 2020 Nov; 140():11-18. PubMed ID: 33032086
[TBL] [Abstract][Full Text] [Related]
19. Melanoma-specific survival in patients with positive sentinel lymph nodes: Relevance of sentinel tumor burden.
Satzger I; Leiter U; Gräger N; Keim U; Garbe C; Gutzmer R
Eur J Cancer; 2019 Dec; 123():83-91. PubMed ID: 31677550
[TBL] [Abstract][Full Text] [Related]
20. Melanoma Prognosis: Accuracy of the American Joint Committee on Cancer Staging Manual Eighth Edition.
Bajaj S; Donnelly D; Call M; Johannet P; Moran U; Polsky D; Shapiro R; Berman R; Pavlick A; Weber J; Zhong J; Osman I
J Natl Cancer Inst; 2020 Sep; 112(9):921-928. PubMed ID: 31977051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
